nodes	percent_of_prediction	percent_of_DWPC	metapath
Betamethasone—CYP19A1—esophageal cancer	0.385	0.54	CbGaD
Betamethasone—PTGS2—esophageal cancer	0.177	0.248	CbGaD
Betamethasone—ABCB1—esophageal cancer	0.15	0.211	CbGaD
Betamethasone—PTGS2—Cisplatin—esophageal cancer	0.0345	0.647	CbGbCtD
Betamethasone—ABCB1—Cisplatin—esophageal cancer	0.0114	0.214	CbGbCtD
Betamethasone—ABCB1—Methotrexate—esophageal cancer	0.00739	0.139	CbGbCtD
Betamethasone—PLA2G1B—exocrine gland—esophageal cancer	0.00675	0.185	CbGeAlD
Betamethasone—Skin depigmentation—Methotrexate—esophageal cancer	0.00444	0.0401	CcSEcCtD
Betamethasone—Mass—Capecitabine—esophageal cancer	0.00343	0.031	CcSEcCtD
Betamethasone—Aseptic necrosis—Methotrexate—esophageal cancer	0.00321	0.029	CcSEcCtD
Betamethasone—PLA2G1B—epithelium—esophageal cancer	0.00294	0.0803	CbGeAlD
Betamethasone—Paraplegia—Methotrexate—esophageal cancer	0.00273	0.0247	CcSEcCtD
Betamethasone—Oesophageal candidiasis—Capecitabine—esophageal cancer	0.00272	0.0246	CcSEcCtD
Betamethasone—Extravasation—Carboplatin—esophageal cancer	0.00264	0.0238	CcSEcCtD
Betamethasone—Personality change—Capecitabine—esophageal cancer	0.00259	0.0234	CcSEcCtD
Betamethasone—Diplegia—Methotrexate—esophageal cancer	0.00255	0.023	CcSEcCtD
Betamethasone—Glucose tolerance impaired—Cisplatin—esophageal cancer	0.0025	0.0226	CcSEcCtD
Betamethasone—Monoplegia—Methotrexate—esophageal cancer	0.00239	0.0216	CcSEcCtD
Betamethasone—PLA2G1B—digestive system—esophageal cancer	0.00223	0.0611	CbGeAlD
Betamethasone—Papilloedema—Cisplatin—esophageal cancer	0.00212	0.0192	CcSEcCtD
Betamethasone—Arachnoiditis—Methotrexate—esophageal cancer	0.00203	0.0183	CcSEcCtD
Betamethasone—PLA2G1B—lung—esophageal cancer	0.00187	0.051	CbGeAlD
Betamethasone—Telangiectasia—Methotrexate—esophageal cancer	0.00157	0.0142	CcSEcCtD
Betamethasone—Amcinonide—ANXA1—esophageal cancer	0.0015	0.293	CrCbGaD
Betamethasone—NR3C2—bronchus—esophageal cancer	0.00143	0.0391	CbGeAlD
Betamethasone—Cognitive impairment—Methotrexate—esophageal cancer	0.00142	0.0128	CcSEcCtD
Betamethasone—NR3C2—smooth muscle tissue—esophageal cancer	0.0014	0.0383	CbGeAlD
Betamethasone—Oesophageal ulcer—Capecitabine—esophageal cancer	0.00136	0.0123	CcSEcCtD
Betamethasone—PGR—epithelium—esophageal cancer	0.00135	0.037	CbGeAlD
Betamethasone—PGR—smooth muscle tissue—esophageal cancer	0.0013	0.0356	CbGeAlD
Betamethasone—NR3C2—trachea—esophageal cancer	0.00129	0.0352	CbGeAlD
Betamethasone—Blindness—Cisplatin—esophageal cancer	0.00122	0.011	CcSEcCtD
Betamethasone—NR3C1—neck—esophageal cancer	0.00115	0.0313	CbGeAlD
Betamethasone—Diabetic—Methotrexate—esophageal cancer	0.00111	0.01	CcSEcCtD
Betamethasone—NR3C2—digestive system—esophageal cancer	0.00111	0.0302	CbGeAlD
Betamethasone—Optic neuritis—Cisplatin—esophageal cancer	0.0011	0.0099	CcSEcCtD
Betamethasone—Osteonecrosis—Methotrexate—esophageal cancer	0.000993	0.00897	CcSEcCtD
Betamethasone—NR3C2—lung—esophageal cancer	0.000924	0.0253	CbGeAlD
Betamethasone—Opportunistic infection—Methotrexate—esophageal cancer	0.000919	0.0083	CcSEcCtD
Betamethasone—Leukoderma—Methotrexate—esophageal cancer	0.000871	0.00786	CcSEcCtD
Betamethasone—Necrosis—Cisplatin—esophageal cancer	0.000859	0.00776	CcSEcCtD
Betamethasone—PGR—lung—esophageal cancer	0.000859	0.0235	CbGeAlD
Betamethasone—Cognitive disorder—Methotrexate—esophageal cancer	0.000856	0.00773	CcSEcCtD
Betamethasone—Impaired healing—Methotrexate—esophageal cancer	0.000856	0.00773	CcSEcCtD
Betamethasone—Hirsutism—Capecitabine—esophageal cancer	0.000855	0.00773	CcSEcCtD
Betamethasone—Abscess—Cisplatin—esophageal cancer	0.000852	0.0077	CcSEcCtD
Betamethasone—Skin hyperpigmentation—Capecitabine—esophageal cancer	0.000836	0.00755	CcSEcCtD
Betamethasone—Visual acuity reduced—Capecitabine—esophageal cancer	0.000836	0.00755	CcSEcCtD
Betamethasone—Infection—Carboplatin—esophageal cancer	0.000815	0.00736	CcSEcCtD
Betamethasone—NR3C1—epithelium—esophageal cancer	0.00078	0.0213	CbGeAlD
Betamethasone—Embolism—Capecitabine—esophageal cancer	0.000774	0.007	CcSEcCtD
Betamethasone—Extravasation—Cisplatin—esophageal cancer	0.000773	0.00698	CcSEcCtD
Betamethasone—NR3C1—bronchus—esophageal cancer	0.000768	0.021	CbGeAlD
Betamethasone—Keratitis—Capecitabine—esophageal cancer	0.000766	0.00692	CcSEcCtD
Betamethasone—NR3C1—smooth muscle tissue—esophageal cancer	0.000752	0.0205	CbGeAlD
Betamethasone—Ulcer—Cisplatin—esophageal cancer	0.000713	0.00644	CcSEcCtD
Betamethasone—Hepatomegaly—Capecitabine—esophageal cancer	0.000702	0.00634	CcSEcCtD
Betamethasone—Pain—Carboplatin—esophageal cancer	0.000701	0.00634	CcSEcCtD
Betamethasone—NR3C1—trachea—esophageal cancer	0.00069	0.0189	CbGeAlD
Betamethasone—Blister—Capecitabine—esophageal cancer	0.00069	0.00623	CcSEcCtD
Betamethasone—PTGS2—epithelium—esophageal cancer	0.000675	0.0185	CbGeAlD
Betamethasone—Hiccups—Cisplatin—esophageal cancer	0.000674	0.00609	CcSEcCtD
Betamethasone—PTGS2—bronchus—esophageal cancer	0.000665	0.0182	CbGeAlD
Betamethasone—Osteoporosis—Methotrexate—esophageal cancer	0.00066	0.00596	CcSEcCtD
Betamethasone—PTGS2—smooth muscle tissue—esophageal cancer	0.000651	0.0178	CbGeAlD
Betamethasone—Rash erythematous—Capecitabine—esophageal cancer	0.000649	0.00586	CcSEcCtD
Betamethasone—Body temperature increased—Carboplatin—esophageal cancer	0.000648	0.00586	CcSEcCtD
Betamethasone—Skin exfoliation—Cisplatin—esophageal cancer	0.000644	0.00582	CcSEcCtD
Betamethasone—Fungal infection—Capecitabine—esophageal cancer	0.000644	0.00582	CcSEcCtD
Betamethasone—Fluid retention—Cisplatin—esophageal cancer	0.00064	0.00578	CcSEcCtD
Betamethasone—Multiple fractures—Methotrexate—esophageal cancer	0.000637	0.00575	CcSEcCtD
Betamethasone—Fracture—Methotrexate—esophageal cancer	0.000637	0.00575	CcSEcCtD
Betamethasone—Neuropathy—Cisplatin—esophageal cancer	0.000633	0.00572	CcSEcCtD
Betamethasone—Hydrocortisone—ANXA1—esophageal cancer	0.000632	0.124	CrCbGaD
Betamethasone—NR3C2—lymph node—esophageal cancer	0.000632	0.0173	CbGeAlD
Betamethasone—Skin hyperpigmentation—Methotrexate—esophageal cancer	0.000622	0.00562	CcSEcCtD
Betamethasone—Tingling sensation—Capecitabine—esophageal cancer	0.000618	0.00559	CcSEcCtD
Betamethasone—Petechiae—Capecitabine—esophageal cancer	0.000604	0.00546	CcSEcCtD
Betamethasone—Testolactone—CYP19A1—esophageal cancer	0.000603	0.118	CrCbGaD
Betamethasone—PTGS2—trachea—esophageal cancer	0.000597	0.0163	CbGeAlD
Betamethasone—NR3C1—digestive system—esophageal cancer	0.000594	0.0162	CbGeAlD
Betamethasone—Folliculitis—Methotrexate—esophageal cancer	0.000589	0.00532	CcSEcCtD
Betamethasone—PGR—lymph node—esophageal cancer	0.000588	0.0161	CbGeAlD
Betamethasone—Embolism—Methotrexate—esophageal cancer	0.000577	0.00521	CcSEcCtD
Betamethasone—Contusion—Capecitabine—esophageal cancer	0.00057	0.00515	CcSEcCtD
Betamethasone—Cardiac failure congestive—Cisplatin—esophageal cancer	0.00054	0.00488	CcSEcCtD
Betamethasone—Herpes simplex—Capecitabine—esophageal cancer	0.000539	0.00487	CcSEcCtD
Betamethasone—CYP19A1—lymph node—esophageal cancer	0.000529	0.0145	CbGeAlD
Betamethasone—Ulcer—Capecitabine—esophageal cancer	0.000526	0.00475	CcSEcCtD
Betamethasone—Cataract—Capecitabine—esophageal cancer	0.000522	0.00472	CcSEcCtD
Betamethasone—PTGS2—digestive system—esophageal cancer	0.000514	0.014	CbGeAlD
Betamethasone—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.000506	0.00457	CcSEcCtD
Betamethasone—Hiccups—Capecitabine—esophageal cancer	0.000497	0.00449	CcSEcCtD
Betamethasone—NR3C1—lung—esophageal cancer	0.000496	0.0135	CbGeAlD
Betamethasone—Fungal infection—Methotrexate—esophageal cancer	0.000479	0.00433	CcSEcCtD
Betamethasone—Skin exfoliation—Capecitabine—esophageal cancer	0.000475	0.00429	CcSEcCtD
Betamethasone—Fluid retention—Capecitabine—esophageal cancer	0.000472	0.00426	CcSEcCtD
Betamethasone—Necrosis—Methotrexate—esophageal cancer	0.000472	0.00426	CcSEcCtD
Betamethasone—Dexamethasone—ANXA1—esophageal cancer	0.000471	0.0921	CrCbGaD
Betamethasone—Abscess—Methotrexate—esophageal cancer	0.000468	0.00423	CcSEcCtD
Betamethasone—Irritability—Cisplatin—esophageal cancer	0.000467	0.00422	CcSEcCtD
Betamethasone—Neuropathy—Capecitabine—esophageal cancer	0.000467	0.00422	CcSEcCtD
Betamethasone—Dry eye—Capecitabine—esophageal cancer	0.000459	0.00415	CcSEcCtD
Betamethasone—Oesophagitis—Capecitabine—esophageal cancer	0.000454	0.0041	CcSEcCtD
Betamethasone—Petechiae—Methotrexate—esophageal cancer	0.00045	0.00406	CcSEcCtD
Betamethasone—Ecchymosis—Capecitabine—esophageal cancer	0.000449	0.00406	CcSEcCtD
Betamethasone—CYP3A4—digestive system—esophageal cancer	0.000449	0.0123	CbGeAlD
Betamethasone—Hypokalaemia—Cisplatin—esophageal cancer	0.000446	0.00402	CcSEcCtD
Betamethasone—PTGS2—lung—esophageal cancer	0.000429	0.0117	CbGeAlD
Betamethasone—Extravasation—Methotrexate—esophageal cancer	0.000424	0.00383	CcSEcCtD
Betamethasone—ABCB1—epithelium—esophageal cancer	0.000418	0.0114	CbGeAlD
Betamethasone—Thrombophlebitis—Capecitabine—esophageal cancer	0.000417	0.00377	CcSEcCtD
Betamethasone—Diabetes mellitus—Capecitabine—esophageal cancer	0.000415	0.00375	CcSEcCtD
Betamethasone—Sweating increased—Cisplatin—esophageal cancer	0.000412	0.00372	CcSEcCtD
Betamethasone—Herpes simplex—Methotrexate—esophageal cancer	0.000402	0.00363	CcSEcCtD
Betamethasone—Eye pain—Capecitabine—esophageal cancer	0.0004	0.00361	CcSEcCtD
Betamethasone—Ulcer—Methotrexate—esophageal cancer	0.000391	0.00353	CcSEcCtD
Betamethasone—Increased appetite—Capecitabine—esophageal cancer	0.000384	0.00347	CcSEcCtD
Betamethasone—Vasculitis—Methotrexate—esophageal cancer	0.000379	0.00343	CcSEcCtD
Betamethasone—Dermatitis bullous—Capecitabine—esophageal cancer	0.000378	0.00341	CcSEcCtD
Betamethasone—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000372	0.00336	CcSEcCtD
Betamethasone—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00037	0.00334	CcSEcCtD
Betamethasone—Myocardial infarction—Cisplatin—esophageal cancer	0.00037	0.00334	CcSEcCtD
Betamethasone—Cardiac failure—Capecitabine—esophageal cancer	0.00037	0.00334	CcSEcCtD
Betamethasone—ABCB1—trachea—esophageal cancer	0.000369	0.0101	CbGeAlD
Betamethasone—Lethargy—Capecitabine—esophageal cancer	0.000368	0.00333	CcSEcCtD
Betamethasone—Conjunctivitis—Cisplatin—esophageal cancer	0.000367	0.00331	CcSEcCtD
Betamethasone—Osteoarthritis—Capecitabine—esophageal cancer	0.000361	0.00326	CcSEcCtD
Betamethasone—Migraine—Capecitabine—esophageal cancer	0.000355	0.00321	CcSEcCtD
Betamethasone—Skin exfoliation—Methotrexate—esophageal cancer	0.000353	0.00319	CcSEcCtD
Betamethasone—Bradycardia—Cisplatin—esophageal cancer	0.000345	0.00311	CcSEcCtD
Betamethasone—Irritability—Capecitabine—esophageal cancer	0.000344	0.00311	CcSEcCtD
Betamethasone—Cardiac arrest—Capecitabine—esophageal cancer	0.000343	0.0031	CcSEcCtD
Betamethasone—Mood swings—Capecitabine—esophageal cancer	0.000342	0.00309	CcSEcCtD
Betamethasone—NR3C1—lymph node—esophageal cancer	0.000339	0.00927	CbGeAlD
Betamethasone—Ecchymosis—Methotrexate—esophageal cancer	0.000335	0.00302	CcSEcCtD
Betamethasone—Dry skin—Capecitabine—esophageal cancer	0.000331	0.00299	CcSEcCtD
Betamethasone—Pulmonary oedema—Methotrexate—esophageal cancer	0.000329	0.00298	CcSEcCtD
Betamethasone—Hypokalaemia—Capecitabine—esophageal cancer	0.000328	0.00297	CcSEcCtD
Betamethasone—Visual impairment—Cisplatin—esophageal cancer	0.000326	0.00295	CcSEcCtD
Betamethasone—Muscular weakness—Capecitabine—esophageal cancer	0.000318	0.00288	CcSEcCtD
Betamethasone—ABCB1—digestive system—esophageal cancer	0.000318	0.00868	CbGeAlD
Betamethasone—Eye disorder—Cisplatin—esophageal cancer	0.000316	0.00286	CcSEcCtD
Betamethasone—Thrombophlebitis—Methotrexate—esophageal cancer	0.00031	0.0028	CcSEcCtD
Betamethasone—Diabetes mellitus—Methotrexate—esophageal cancer	0.000309	0.00279	CcSEcCtD
Betamethasone—Sweating increased—Capecitabine—esophageal cancer	0.000304	0.00274	CcSEcCtD
Betamethasone—Arrhythmia—Cisplatin—esophageal cancer	0.000303	0.00273	CcSEcCtD
Betamethasone—Alopecia—Cisplatin—esophageal cancer	0.000299	0.0027	CcSEcCtD
Betamethasone—Erythema—Cisplatin—esophageal cancer	0.000295	0.00266	CcSEcCtD
Betamethasone—PTGS2—lymph node—esophageal cancer	0.000293	0.00802	CbGeAlD
Betamethasone—Weight increased—Capecitabine—esophageal cancer	0.000284	0.00256	CcSEcCtD
Betamethasone—Visual disturbance—Methotrexate—esophageal cancer	0.000283	0.00256	CcSEcCtD
Betamethasone—Weight decreased—Capecitabine—esophageal cancer	0.000282	0.00255	CcSEcCtD
Betamethasone—Hyperglycaemia—Capecitabine—esophageal cancer	0.000281	0.00254	CcSEcCtD
Betamethasone—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000278	0.00251	CcSEcCtD
Betamethasone—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000274	0.00248	CcSEcCtD
Betamethasone—Lethargy—Methotrexate—esophageal cancer	0.000274	0.00248	CcSEcCtD
Betamethasone—Ill-defined disorder—Cisplatin—esophageal cancer	0.000274	0.00247	CcSEcCtD
Betamethasone—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000273	0.00246	CcSEcCtD
Betamethasone—Myocardial infarction—Capecitabine—esophageal cancer	0.000273	0.00246	CcSEcCtD
Betamethasone—Conjunctivitis—Capecitabine—esophageal cancer	0.00027	0.00244	CcSEcCtD
Betamethasone—Osteoarthritis—Methotrexate—esophageal cancer	0.000269	0.00243	CcSEcCtD
Betamethasone—Malaise—Cisplatin—esophageal cancer	0.000266	0.0024	CcSEcCtD
Betamethasone—ABCB1—lung—esophageal cancer	0.000265	0.00725	CbGeAlD
Betamethasone—Irritability—Methotrexate—esophageal cancer	0.000256	0.00232	CcSEcCtD
Betamethasone—Convulsion—Cisplatin—esophageal cancer	0.000255	0.00231	CcSEcCtD
Betamethasone—Mood swings—Methotrexate—esophageal cancer	0.000254	0.0023	CcSEcCtD
Betamethasone—Bradycardia—Capecitabine—esophageal cancer	0.000254	0.0023	CcSEcCtD
Betamethasone—Prednisolone—CYP2A6—esophageal cancer	0.000254	0.0496	CrCbGaD
Betamethasone—Myalgia—Cisplatin—esophageal cancer	0.000251	0.00227	CcSEcCtD
Betamethasone—Haemoglobin—Capecitabine—esophageal cancer	0.000251	0.00227	CcSEcCtD
Betamethasone—Anxiety—Cisplatin—esophageal cancer	0.00025	0.00226	CcSEcCtD
Betamethasone—Haemorrhage—Capecitabine—esophageal cancer	0.00025	0.00226	CcSEcCtD
Betamethasone—Discomfort—Cisplatin—esophageal cancer	0.000248	0.00224	CcSEcCtD
Betamethasone—Oedema—Cisplatin—esophageal cancer	0.000241	0.00217	CcSEcCtD
Betamethasone—Anaphylactic shock—Cisplatin—esophageal cancer	0.000241	0.00217	CcSEcCtD
Betamethasone—Visual impairment—Capecitabine—esophageal cancer	0.000241	0.00217	CcSEcCtD
Betamethasone—Infection—Cisplatin—esophageal cancer	0.000239	0.00216	CcSEcCtD
Betamethasone—Nervous system disorder—Cisplatin—esophageal cancer	0.000236	0.00213	CcSEcCtD
Betamethasone—Thrombocytopenia—Cisplatin—esophageal cancer	0.000236	0.00213	CcSEcCtD
Betamethasone—Tachycardia—Cisplatin—esophageal cancer	0.000235	0.00212	CcSEcCtD
Betamethasone—Eye disorder—Capecitabine—esophageal cancer	0.000233	0.00211	CcSEcCtD
Betamethasone—Hyperhidrosis—Cisplatin—esophageal cancer	0.000233	0.0021	CcSEcCtD
Betamethasone—Anorexia—Cisplatin—esophageal cancer	0.000229	0.00207	CcSEcCtD
Betamethasone—Angiopathy—Capecitabine—esophageal cancer	0.000226	0.00205	CcSEcCtD
Betamethasone—Hypotension—Cisplatin—esophageal cancer	0.000225	0.00203	CcSEcCtD
Betamethasone—Arrhythmia—Capecitabine—esophageal cancer	0.000223	0.00201	CcSEcCtD
Betamethasone—Alopecia—Capecitabine—esophageal cancer	0.000221	0.00199	CcSEcCtD
Betamethasone—Dexamethasone—NOS2—esophageal cancer	0.000221	0.0431	CrCbGaD
Betamethasone—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000219	0.00198	CcSEcCtD
Betamethasone—Erythema—Capecitabine—esophageal cancer	0.000217	0.00196	CcSEcCtD
Betamethasone—Paraesthesia—Cisplatin—esophageal cancer	0.000216	0.00195	CcSEcCtD
Betamethasone—Decreased appetite—Cisplatin—esophageal cancer	0.000209	0.00189	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000208	0.00188	CcSEcCtD
Betamethasone—Pain—Cisplatin—esophageal cancer	0.000206	0.00186	CcSEcCtD
Betamethasone—Ill-defined disorder—Capecitabine—esophageal cancer	0.000202	0.00182	CcSEcCtD
Betamethasone—Conjunctivitis—Methotrexate—esophageal cancer	0.000201	0.00182	CcSEcCtD
Betamethasone—Feeling abnormal—Cisplatin—esophageal cancer	0.000198	0.00179	CcSEcCtD
Betamethasone—Malaise—Capecitabine—esophageal cancer	0.000196	0.00177	CcSEcCtD
Betamethasone—Vertigo—Capecitabine—esophageal cancer	0.000195	0.00176	CcSEcCtD
Betamethasone—Syncope—Capecitabine—esophageal cancer	0.000195	0.00176	CcSEcCtD
Betamethasone—Loss of consciousness—Capecitabine—esophageal cancer	0.000191	0.00173	CcSEcCtD
Betamethasone—Body temperature increased—Cisplatin—esophageal cancer	0.00019	0.00172	CcSEcCtD
Betamethasone—Hypertension—Capecitabine—esophageal cancer	0.000188	0.00169	CcSEcCtD
Betamethasone—Dexamethasone—CYP1B1—esophageal cancer	0.000188	0.0366	CrCbGaD
Betamethasone—Haemoglobin—Methotrexate—esophageal cancer	0.000187	0.00169	CcSEcCtD
Betamethasone—Haemorrhage—Methotrexate—esophageal cancer	0.000186	0.00168	CcSEcCtD
Betamethasone—Myalgia—Capecitabine—esophageal cancer	0.000185	0.00167	CcSEcCtD
Betamethasone—Anxiety—Capecitabine—esophageal cancer	0.000184	0.00167	CcSEcCtD
Betamethasone—Discomfort—Capecitabine—esophageal cancer	0.000183	0.00165	CcSEcCtD
Betamethasone—ABCB1—lymph node—esophageal cancer	0.000182	0.00496	CbGeAlD
Betamethasone—Visual impairment—Methotrexate—esophageal cancer	0.000179	0.00162	CcSEcCtD
Betamethasone—Oedema—Capecitabine—esophageal cancer	0.000177	0.0016	CcSEcCtD
Betamethasone—Infection—Capecitabine—esophageal cancer	0.000176	0.00159	CcSEcCtD
Betamethasone—Shock—Capecitabine—esophageal cancer	0.000174	0.00158	CcSEcCtD
Betamethasone—Nervous system disorder—Capecitabine—esophageal cancer	0.000174	0.00157	CcSEcCtD
Betamethasone—Eye disorder—Methotrexate—esophageal cancer	0.000174	0.00157	CcSEcCtD
Betamethasone—Thrombocytopenia—Capecitabine—esophageal cancer	0.000174	0.00157	CcSEcCtD
Betamethasone—Tachycardia—Capecitabine—esophageal cancer	0.000173	0.00156	CcSEcCtD
Betamethasone—Asthenia—Cisplatin—esophageal cancer	0.000173	0.00156	CcSEcCtD
Betamethasone—Hyperhidrosis—Capecitabine—esophageal cancer	0.000171	0.00155	CcSEcCtD
Betamethasone—Anorexia—Capecitabine—esophageal cancer	0.000169	0.00153	CcSEcCtD
Betamethasone—Angiopathy—Methotrexate—esophageal cancer	0.000169	0.00152	CcSEcCtD
Betamethasone—Fluticasone furoate—ABCB1—esophageal cancer	0.000168	0.0328	CrCbGaD
Betamethasone—Hypotension—Capecitabine—esophageal cancer	0.000166	0.0015	CcSEcCtD
Betamethasone—Diarrhoea—Cisplatin—esophageal cancer	0.000165	0.00149	CcSEcCtD
Betamethasone—Alopecia—Methotrexate—esophageal cancer	0.000164	0.00148	CcSEcCtD
Betamethasone—Erythema—Methotrexate—esophageal cancer	0.000162	0.00146	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000162	0.00146	CcSEcCtD
Betamethasone—Insomnia—Capecitabine—esophageal cancer	0.00016	0.00145	CcSEcCtD
Betamethasone—Paraesthesia—Capecitabine—esophageal cancer	0.000159	0.00144	CcSEcCtD
Betamethasone—Dyspepsia—Capecitabine—esophageal cancer	0.000156	0.00141	CcSEcCtD
Betamethasone—Decreased appetite—Capecitabine—esophageal cancer	0.000154	0.00139	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000153	0.00138	CcSEcCtD
Betamethasone—Vomiting—Cisplatin—esophageal cancer	0.000153	0.00138	CcSEcCtD
Betamethasone—Fatigue—Capecitabine—esophageal cancer	0.000153	0.00138	CcSEcCtD
Betamethasone—Rash—Cisplatin—esophageal cancer	0.000152	0.00137	CcSEcCtD
Betamethasone—Pain—Capecitabine—esophageal cancer	0.000152	0.00137	CcSEcCtD
Betamethasone—Dermatitis—Cisplatin—esophageal cancer	0.000152	0.00137	CcSEcCtD
Betamethasone—Ill-defined disorder—Methotrexate—esophageal cancer	0.00015	0.00136	CcSEcCtD
Betamethasone—Dexamethasone—ABCC2—esophageal cancer	0.000146	0.0286	CrCbGaD
Betamethasone—Feeling abnormal—Capecitabine—esophageal cancer	0.000146	0.00132	CcSEcCtD
Betamethasone—Malaise—Methotrexate—esophageal cancer	0.000146	0.00132	CcSEcCtD
Betamethasone—Vertigo—Methotrexate—esophageal cancer	0.000145	0.00131	CcSEcCtD
Betamethasone—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000145	0.00131	CcSEcCtD
Betamethasone—Dexamethasone—CYP2A6—esophageal cancer	0.000145	0.0283	CrCbGaD
Betamethasone—Nausea—Cisplatin—esophageal cancer	0.000143	0.00129	CcSEcCtD
Betamethasone—Urticaria—Capecitabine—esophageal cancer	0.000141	0.00127	CcSEcCtD
Betamethasone—Abdominal pain—Capecitabine—esophageal cancer	0.00014	0.00127	CcSEcCtD
Betamethasone—Body temperature increased—Capecitabine—esophageal cancer	0.00014	0.00127	CcSEcCtD
Betamethasone—Convulsion—Methotrexate—esophageal cancer	0.00014	0.00127	CcSEcCtD
Betamethasone—Myalgia—Methotrexate—esophageal cancer	0.000138	0.00124	CcSEcCtD
Betamethasone—Dexamethasone—CYP19A1—esophageal cancer	0.000138	0.0269	CrCbGaD
Betamethasone—Discomfort—Methotrexate—esophageal cancer	0.000136	0.00123	CcSEcCtD
Betamethasone—Methylprednisolone—ABCB1—esophageal cancer	0.000134	0.0262	CrCbGaD
Betamethasone—Triamcinolone—PTGS2—esophageal cancer	0.000133	0.026	CrCbGaD
Betamethasone—Anaphylactic shock—Methotrexate—esophageal cancer	0.000132	0.00119	CcSEcCtD
Betamethasone—Infection—Methotrexate—esophageal cancer	0.000131	0.00118	CcSEcCtD
Betamethasone—Nervous system disorder—Methotrexate—esophageal cancer	0.000129	0.00117	CcSEcCtD
Betamethasone—Thrombocytopenia—Methotrexate—esophageal cancer	0.000129	0.00117	CcSEcCtD
Betamethasone—Hyperhidrosis—Methotrexate—esophageal cancer	0.000128	0.00115	CcSEcCtD
Betamethasone—Asthenia—Capecitabine—esophageal cancer	0.000127	0.00115	CcSEcCtD
Betamethasone—Anorexia—Methotrexate—esophageal cancer	0.000126	0.00114	CcSEcCtD
Betamethasone—Pruritus—Capecitabine—esophageal cancer	0.000125	0.00113	CcSEcCtD
Betamethasone—Hypotension—Methotrexate—esophageal cancer	0.000123	0.00111	CcSEcCtD
Betamethasone—Diarrhoea—Capecitabine—esophageal cancer	0.000121	0.0011	CcSEcCtD
Betamethasone—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00012	0.00109	CcSEcCtD
Betamethasone—Insomnia—Methotrexate—esophageal cancer	0.000119	0.00108	CcSEcCtD
Betamethasone—Paraesthesia—Methotrexate—esophageal cancer	0.000119	0.00107	CcSEcCtD
Betamethasone—Dizziness—Capecitabine—esophageal cancer	0.000117	0.00106	CcSEcCtD
Betamethasone—Dyspepsia—Methotrexate—esophageal cancer	0.000116	0.00105	CcSEcCtD
Betamethasone—Decreased appetite—Methotrexate—esophageal cancer	0.000115	0.00104	CcSEcCtD
Betamethasone—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000114	0.00103	CcSEcCtD
Betamethasone—Fatigue—Methotrexate—esophageal cancer	0.000114	0.00103	CcSEcCtD
Betamethasone—Pain—Methotrexate—esophageal cancer	0.000113	0.00102	CcSEcCtD
Betamethasone—Vomiting—Capecitabine—esophageal cancer	0.000113	0.00102	CcSEcCtD
Betamethasone—Rash—Capecitabine—esophageal cancer	0.000112	0.00101	CcSEcCtD
Betamethasone—Dermatitis—Capecitabine—esophageal cancer	0.000112	0.00101	CcSEcCtD
Betamethasone—Headache—Capecitabine—esophageal cancer	0.000111	0.001	CcSEcCtD
Betamethasone—Feeling abnormal—Methotrexate—esophageal cancer	0.000109	0.000983	CcSEcCtD
Betamethasone—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000108	0.000975	CcSEcCtD
Betamethasone—Nausea—Capecitabine—esophageal cancer	0.000105	0.000952	CcSEcCtD
Betamethasone—Urticaria—Methotrexate—esophageal cancer	0.000105	0.000948	CcSEcCtD
Betamethasone—Abdominal pain—Methotrexate—esophageal cancer	0.000104	0.000943	CcSEcCtD
Betamethasone—Body temperature increased—Methotrexate—esophageal cancer	0.000104	0.000943	CcSEcCtD
Betamethasone—Prednisone—ABCB1—esophageal cancer	0.000102	0.02	CrCbGaD
Betamethasone—Asthenia—Methotrexate—esophageal cancer	9.47e-05	0.000856	CcSEcCtD
Betamethasone—Prednisolone—ABCB1—esophageal cancer	9.44e-05	0.0185	CrCbGaD
Betamethasone—Pruritus—Methotrexate—esophageal cancer	9.34e-05	0.000844	CcSEcCtD
Betamethasone—Diarrhoea—Methotrexate—esophageal cancer	9.03e-05	0.000816	CcSEcCtD
Betamethasone—Dizziness—Methotrexate—esophageal cancer	8.73e-05	0.000789	CcSEcCtD
Betamethasone—Vomiting—Methotrexate—esophageal cancer	8.39e-05	0.000758	CcSEcCtD
Betamethasone—Rash—Methotrexate—esophageal cancer	8.32e-05	0.000752	CcSEcCtD
Betamethasone—Dermatitis—Methotrexate—esophageal cancer	8.32e-05	0.000751	CcSEcCtD
Betamethasone—Headache—Methotrexate—esophageal cancer	8.27e-05	0.000747	CcSEcCtD
Betamethasone—Nausea—Methotrexate—esophageal cancer	7.84e-05	0.000708	CcSEcCtD
Betamethasone—Hydrocortisone—ABCB1—esophageal cancer	7.22e-05	0.0141	CrCbGaD
Betamethasone—Dexamethasone—PTGS2—esophageal cancer	6.33e-05	0.0124	CrCbGaD
Betamethasone—Dexamethasone—ABCB1—esophageal cancer	5.38e-05	0.0105	CrCbGaD
Betamethasone—NR3C2—Gene Expression—NOTCH1—esophageal cancer	4.33e-05	0.000527	CbGpPWpGaD
Betamethasone—NR3C1—Generic Transcription Pathway—SMAD4—esophageal cancer	4.29e-05	0.000523	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—NOTCH2—esophageal cancer	4.26e-05	0.000519	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—HIST1H2BM—esophageal cancer	4.22e-05	0.000514	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—PDE4D—esophageal cancer	4.18e-05	0.000509	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—ADH1B—esophageal cancer	4.14e-05	0.000505	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—GNG7—esophageal cancer	3.97e-05	0.000484	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—TYMP—esophageal cancer	3.96e-05	0.000482	CbGpPWpGaD
Betamethasone—NR3C2—Gene Expression—CREBBP—esophageal cancer	3.92e-05	0.000478	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	3.9e-05	0.000476	CbGpPWpGaD
Betamethasone—PTGS2—Disease—FKBP1A—esophageal cancer	3.86e-05	0.00047	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—CYP26A1—esophageal cancer	3.85e-05	0.000469	CbGpPWpGaD
Betamethasone—CYP19A1—Integrated Breast Cancer Pathway—TP53—esophageal cancer	3.85e-05	0.000469	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—MYC—esophageal cancer	3.82e-05	0.000465	CbGpPWpGaD
Betamethasone—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	3.78e-05	0.00046	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.77e-05	0.00046	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	3.77e-05	0.000459	CbGpPWpGaD
Betamethasone—PTGS2—Disease—DOCK2—esophageal cancer	3.77e-05	0.000459	CbGpPWpGaD
Betamethasone—PTGS2—Disease—WIF1—esophageal cancer	3.77e-05	0.000459	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—ALOX15—esophageal cancer	3.75e-05	0.000457	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—HIST1H2BM—esophageal cancer	3.75e-05	0.000457	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—EGFR—esophageal cancer	3.73e-05	0.000455	CbGpPWpGaD
Betamethasone—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	3.72e-05	0.000454	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—XIAP—esophageal cancer	3.72e-05	0.000454	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—CA1—esophageal cancer	3.71e-05	0.000452	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—SLC10A2—esophageal cancer	3.71e-05	0.000452	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	3.66e-05	0.000446	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—TPI1—esophageal cancer	3.58e-05	0.000436	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—GSTO1—esophageal cancer	3.58e-05	0.000436	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—SMAD4—esophageal cancer	3.57e-05	0.000435	CbGpPWpGaD
Betamethasone—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	3.55e-05	0.000432	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—CTNNA1—esophageal cancer	3.52e-05	0.000429	CbGpPWpGaD
Betamethasone—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	3.5e-05	0.000427	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—CXCL2—esophageal cancer	3.5e-05	0.000427	CbGpPWpGaD
Betamethasone—PTGS2—Disease—CSNK1A1—esophageal cancer	3.48e-05	0.000424	CbGpPWpGaD
Betamethasone—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	3.47e-05	0.000423	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—ALDOB—esophageal cancer	3.43e-05	0.000418	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—CA2—esophageal cancer	3.4e-05	0.000414	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—CREBBP—esophageal cancer	3.33e-05	0.000406	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	3.32e-05	0.000404	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—GAPDH—esophageal cancer	3.3e-05	0.000403	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—CRABP1—esophageal cancer	3.28e-05	0.000399	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—PSME2—esophageal cancer	3.27e-05	0.000398	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—PSME1—esophageal cancer	3.27e-05	0.000398	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—ANXA1—esophageal cancer	3.25e-05	0.000397	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	3.24e-05	0.000394	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—SST—esophageal cancer	3.17e-05	0.000386	CbGpPWpGaD
Betamethasone—NR3C1—Generic Transcription Pathway—NOTCH1—esophageal cancer	3.16e-05	0.000385	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—ADH7—esophageal cancer	3.16e-05	0.000385	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—PLCE1—esophageal cancer	3.16e-05	0.000385	CbGpPWpGaD
Betamethasone—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	3.15e-05	0.000384	CbGpPWpGaD
Betamethasone—PTGS2—Spinal Cord Injury—TP53—esophageal cancer	3.13e-05	0.000382	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	3.13e-05	0.000382	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	3.12e-05	0.00038	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	3.12e-05	0.00038	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—GNG7—esophageal cancer	3.12e-05	0.00038	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	3.1e-05	0.000378	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—SLC52A3—esophageal cancer	3.1e-05	0.000377	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—BLVRB—esophageal cancer	3.1e-05	0.000377	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—GHRL—esophageal cancer	3.09e-05	0.000376	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—NOTCH3—esophageal cancer	3.09e-05	0.000376	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—FBXW7—esophageal cancer	3.04e-05	0.00037	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—NOS3—esophageal cancer	2.99e-05	0.000364	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	2.98e-05	0.000363	CbGpPWpGaD
Betamethasone—PGR—Generic Transcription Pathway—MYC—esophageal cancer	2.94e-05	0.000359	CbGpPWpGaD
Betamethasone—PTGS2—Disease—ELMO1—esophageal cancer	2.92e-05	0.000356	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—ALDH2—esophageal cancer	2.92e-05	0.000356	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—PSME2—esophageal cancer	2.91e-05	0.000354	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—PSME1—esophageal cancer	2.91e-05	0.000354	CbGpPWpGaD
Betamethasone—NR3C1—Generic Transcription Pathway—CREBBP—esophageal cancer	2.87e-05	0.000349	CbGpPWpGaD
Betamethasone—PTGS2—Disease—GSTO1—esophageal cancer	2.86e-05	0.000348	CbGpPWpGaD
Betamethasone—PTGS2—Disease—TPI1—esophageal cancer	2.86e-05	0.000348	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—GSTT1—esophageal cancer	2.78e-05	0.000338	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—ADH1B—esophageal cancer	2.77e-05	0.000337	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—NOTCH2—esophageal cancer	2.77e-05	0.000337	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—CYP2A6—esophageal cancer	2.74e-05	0.000334	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—NOTCH3—esophageal cancer	2.74e-05	0.000334	CbGpPWpGaD
Betamethasone—PTGS2—Disease—ALDOB—esophageal cancer	2.74e-05	0.000334	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.73e-05	0.000333	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—PTGS2—esophageal cancer	2.73e-05	0.000333	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	2.67e-05	0.000326	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—TYMP—esophageal cancer	2.65e-05	0.000322	CbGpPWpGaD
Betamethasone—PTGS2—Disease—HIST1H2BM—esophageal cancer	2.64e-05	0.000321	CbGpPWpGaD
Betamethasone—PTGS2—Disease—GAPDH—esophageal cancer	2.64e-05	0.000321	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—NOTCH1—esophageal cancer	2.63e-05	0.000321	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—CA1—esophageal cancer	2.63e-05	0.000321	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—SLC10A2—esophageal cancer	2.63e-05	0.000321	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—ENO1—esophageal cancer	2.6e-05	0.000317	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PTGS1—esophageal cancer	2.6e-05	0.000317	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	2.6e-05	0.000316	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	2.6e-05	0.000316	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—CYP26A1—esophageal cancer	2.57e-05	0.000314	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PSME2—esophageal cancer	2.56e-05	0.000312	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PSME1—esophageal cancer	2.56e-05	0.000312	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	2.54e-05	0.000309	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	2.54e-05	0.000309	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—ALOX15—esophageal cancer	2.51e-05	0.000306	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—NOTCH2—esophageal cancer	2.46e-05	0.0003	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—TGFBR2—esophageal cancer	2.45e-05	0.000299	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—CA2—esophageal cancer	2.41e-05	0.000293	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GSTO1—esophageal cancer	2.39e-05	0.000292	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—TPI1—esophageal cancer	2.39e-05	0.000292	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—CREBBP—esophageal cancer	2.39e-05	0.000291	CbGpPWpGaD
Betamethasone—PTGS2—Disease—XIAP—esophageal cancer	2.33e-05	0.000284	CbGpPWpGaD
Betamethasone—NR3C2—Gene Expression—MYC—esophageal cancer	2.33e-05	0.000284	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—SMAD4—esophageal cancer	2.32e-05	0.000283	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	2.29e-05	0.00028	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—ALDOB—esophageal cancer	2.29e-05	0.00028	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—EP300—esophageal cancer	2.27e-05	0.000277	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.24e-05	0.000273	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PLCE1—esophageal cancer	2.24e-05	0.000273	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—ADH7—esophageal cancer	2.24e-05	0.000273	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	2.22e-05	0.00027	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—CYP1B1—esophageal cancer	2.21e-05	0.00027	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GAPDH—esophageal cancer	2.21e-05	0.000269	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.2e-05	0.000269	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—CRABP1—esophageal cancer	2.19e-05	0.000267	CbGpPWpGaD
Betamethasone—PTGS2—Disease—B2M—esophageal cancer	2.17e-05	0.000264	CbGpPWpGaD
Betamethasone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.13e-05	0.00026	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	2.11e-05	0.000257	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GNG7—esophageal cancer	2.08e-05	0.000254	CbGpPWpGaD
Betamethasone—PTGS2—Disease—ENO1—esophageal cancer	2.08e-05	0.000253	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—SMAD4—esophageal cancer	2.07e-05	0.000252	CbGpPWpGaD
Betamethasone—PTGS2—Disease—PSME2—esophageal cancer	2.05e-05	0.000249	CbGpPWpGaD
Betamethasone—PTGS2—Disease—PSME1—esophageal cancer	2.05e-05	0.000249	CbGpPWpGaD
Betamethasone—PTGS2—Disease—CALR—esophageal cancer	1.96e-05	0.000239	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—ADH1B—esophageal cancer	1.96e-05	0.000239	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—ALDH2—esophageal cancer	1.95e-05	0.000238	CbGpPWpGaD
Betamethasone—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.92e-05	0.000234	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—BLVRB—esophageal cancer	1.91e-05	0.000232	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—SLC52A3—esophageal cancer	1.91e-05	0.000232	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—HIF1A—esophageal cancer	1.9e-05	0.000232	CbGpPWpGaD
Betamethasone—PTGS2—Disease—FBXW7—esophageal cancer	1.9e-05	0.000231	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—HMOX1—esophageal cancer	1.9e-05	0.000231	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—TYMP—esophageal cancer	1.88e-05	0.000229	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.86e-05	0.000227	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—GSTT1—esophageal cancer	1.86e-05	0.000226	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	1.84e-05	0.000224	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—CYP2A6—esophageal cancer	1.83e-05	0.000223	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.83e-05	0.000223	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—CYP26A1—esophageal cancer	1.82e-05	0.000222	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—ABCB1—esophageal cancer	1.82e-05	0.000222	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—KDR—esophageal cancer	1.82e-05	0.000222	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	1.8e-05	0.000219	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—ALOX15—esophageal cancer	1.78e-05	0.000217	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—PTGS1—esophageal cancer	1.74e-05	0.000212	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—ENO1—esophageal cancer	1.74e-05	0.000212	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—PSME2—esophageal cancer	1.71e-05	0.000209	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—PSME1—esophageal cancer	1.71e-05	0.000209	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—NOTCH1—esophageal cancer	1.71e-05	0.000209	CbGpPWpGaD
Betamethasone—NR3C1—Generic Transcription Pathway—MYC—esophageal cancer	1.7e-05	0.000207	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GSTO1—esophageal cancer	1.7e-05	0.000207	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—TPI1—esophageal cancer	1.7e-05	0.000207	CbGpPWpGaD
Betamethasone—PLA2G1B—Metabolism—PIK3CA—esophageal cancer	1.68e-05	0.000205	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—ALDOB—esophageal cancer	1.63e-05	0.000198	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—SLC10A2—esophageal cancer	1.62e-05	0.000198	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—CA1—esophageal cancer	1.62e-05	0.000198	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GAPDH—esophageal cancer	1.57e-05	0.000191	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.56e-05	0.00019	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—CREBBP—esophageal cancer	1.55e-05	0.000189	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—CRABP1—esophageal cancer	1.55e-05	0.000189	CbGpPWpGaD
Betamethasone—PTGS2—Disease—TGFBR2—esophageal cancer	1.54e-05	0.000187	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—NOTCH1—esophageal cancer	1.52e-05	0.000186	CbGpPWpGaD
Betamethasone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.51e-05	0.000184	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—CA2—esophageal cancer	1.48e-05	0.000181	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—CYP1B1—esophageal cancer	1.48e-05	0.00018	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GNG7—esophageal cancer	1.48e-05	0.00018	CbGpPWpGaD
Betamethasone—PTGS2—Disease—SMAD4—esophageal cancer	1.45e-05	0.000177	CbGpPWpGaD
Betamethasone—PGR—Gene Expression—MYC—esophageal cancer	1.42e-05	0.000173	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—NOS3—esophageal cancer	1.39e-05	0.000169	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—CYP19A1—esophageal cancer	1.39e-05	0.000169	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—ALDH2—esophageal cancer	1.38e-05	0.000168	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—CREBBP—esophageal cancer	1.38e-05	0.000168	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.38e-05	0.000168	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—ADH7—esophageal cancer	1.38e-05	0.000168	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.38e-05	0.000168	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—GSTT1—esophageal cancer	1.32e-05	0.00016	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—ERBB2—esophageal cancer	1.3e-05	0.000158	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—CYP2A6—esophageal cancer	1.3e-05	0.000158	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—HMOX1—esophageal cancer	1.27e-05	0.000155	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.24e-05	0.000152	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—ENO1—esophageal cancer	1.23e-05	0.00015	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PTGS1—esophageal cancer	1.23e-05	0.00015	CbGpPWpGaD
Betamethasone—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.23e-05	0.00015	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—CREBBP—esophageal cancer	1.22e-05	0.000148	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—ABCB1—esophageal cancer	1.22e-05	0.000148	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PSME2—esophageal cancer	1.21e-05	0.000148	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PSME1—esophageal cancer	1.21e-05	0.000148	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.21e-05	0.000147	CbGpPWpGaD
Betamethasone—PTGS2—Disease—HIF1A—esophageal cancer	1.19e-05	0.000145	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—TYMP—esophageal cancer	1.16e-05	0.000141	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—CCND1—esophageal cancer	1.15e-05	0.00014	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.12e-05	0.000137	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—CDKN1A—esophageal cancer	1.11e-05	0.000135	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.1e-05	0.000133	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—NOS3—esophageal cancer	1.09e-05	0.000133	CbGpPWpGaD
Betamethasone—PTGS2—Disease—NOS2—esophageal cancer	1.08e-05	0.000132	CbGpPWpGaD
Betamethasone—PTGS2—Disease—NOTCH1—esophageal cancer	1.07e-05	0.000131	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—EP300—esophageal cancer	1.06e-05	0.000129	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.05e-05	0.000128	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.05e-05	0.000127	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—TPI1—esophageal cancer	1.05e-05	0.000127	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—ALDOB—esophageal cancer	1e-05	0.000122	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PTGS2—esophageal cancer	9.97e-06	0.000121	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—CYP19A1—esophageal cancer	9.85e-06	0.00012	CbGpPWpGaD
Betamethasone—PTGS2—Disease—CREBBP—esophageal cancer	9.72e-06	0.000118	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GAPDH—esophageal cancer	9.64e-06	0.000118	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—CRABP1—esophageal cancer	9.56e-06	0.000116	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—MYC—esophageal cancer	9.22e-06	0.000112	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	9.2e-06	0.000112	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GNG7—esophageal cancer	9.09e-06	0.000111	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—EGFR—esophageal cancer	9.02e-06	0.00011	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—HMOX1—esophageal cancer	8.99e-06	0.00011	CbGpPWpGaD
Betamethasone—PTGS2—Disease—NOS3—esophageal cancer	8.7e-06	0.000106	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—ALDH2—esophageal cancer	8.52e-06	0.000104	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—EP300—esophageal cancer	8.29e-06	0.000101	CbGpPWpGaD
Betamethasone—NR3C1—Gene Expression—MYC—esophageal cancer	8.19e-06	9.98e-05	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—CREBBP—esophageal cancer	8.14e-06	9.91e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—ERBB2—esophageal cancer	8.14e-06	9.91e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—GSTT1—esophageal cancer	8.1e-06	9.87e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—CYP2A6—esophageal cancer	8.01e-06	9.76e-05	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—PIK3CA—esophageal cancer	7.82e-06	9.53e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PTGS1—esophageal cancer	7.59e-06	9.25e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—ENO1—esophageal cancer	7.59e-06	9.25e-05	CbGpPWpGaD
Betamethasone—PGR—Signaling Pathways—TP53—esophageal cancer	7.57e-06	9.22e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PSME2—esophageal cancer	7.48e-06	9.12e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PSME1—esophageal cancer	7.48e-06	9.12e-05	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—NOS3—esophageal cancer	7.28e-06	8.88e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—CDKN1A—esophageal cancer	6.95e-06	8.47e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—EP300—esophageal cancer	6.62e-06	8.06e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—CYP1B1—esophageal cancer	6.46e-06	7.87e-05	CbGpPWpGaD
Betamethasone—CYP19A1—Metabolism—PIK3CA—esophageal cancer	6.13e-06	7.47e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—CYP19A1—esophageal cancer	6.07e-06	7.4e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—CREBBP—esophageal cancer	5.77e-06	7.03e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—MYC—esophageal cancer	5.77e-06	7.02e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—EGFR—esophageal cancer	5.64e-06	6.87e-05	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—EP300—esophageal cancer	5.54e-06	6.75e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—HMOX1—esophageal cancer	5.54e-06	6.75e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—ABCB1—esophageal cancer	5.32e-06	6.48e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—NOS3—esophageal cancer	5.16e-06	6.29e-05	CbGpPWpGaD
Betamethasone—PTGS2—Disease—PIK3CA—esophageal cancer	4.89e-06	5.96e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PTGS2—esophageal cancer	4.72e-06	5.75e-05	CbGpPWpGaD
Betamethasone—PTGS2—Metabolism—PIK3CA—esophageal cancer	4.1e-06	4.99e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—EP300—esophageal cancer	3.93e-06	4.79e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—CREBBP—esophageal cancer	3.55e-06	4.33e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—NOS3—esophageal cancer	3.18e-06	3.88e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.91e-06	3.55e-05	CbGpPWpGaD
Betamethasone—ABCB1—Metabolism—PIK3CA—esophageal cancer	2.91e-06	3.54e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—EP300—esophageal cancer	2.42e-06	2.95e-05	CbGpPWpGaD
Betamethasone—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.79e-06	2.18e-05	CbGpPWpGaD
